Increase in the number of patients treated and gains in operational efficiency explain record results<\/i><\/p>\n
SÃO PAULO, April 2, 2024<\/span> \/PRNewswire\/ — Oncoclínicas&Co (B3: ONCO3) \u2013 the largest group dedicated to cancer treatment in Latin America<\/span> \u2013 reported a 35.1% growth in its gross revenue in 2023, totaling R$6.0 billion<\/span>. This performance was mainly due to the growth in the number of patients treated, with around 635 thousand procedures performed, an increase of 26.8% compared to 2022. In the fourth quarter of 2023 (4Q23), gross revenue reached R$1.6 billion<\/span>, an organic growth of 18.7% compared to the same period in 2022. The Company continued to grow at an accelerated pace, not only because of the greater number of patients in its units, but also due to its various strategic partnerships with health plans and operators, without compromising on excellence in patient care.<\/p>\n In 2023, gross cash profit totaled R$1.9 billion<\/span>, corresponding to a margin of 35.4%, which represents an increase of 33.7% over that reported in 2022. EBITDA totaled R$1.0 billion<\/span> for the entire year (R$1.1 billion<\/span> excluding the non-cash effect of the long-term incentive plan accounting calculation, or on an ex-PILP basis), 58.9% above 2022, reflecting not only the Company’s revenue growth, but also efficiency gains captured in the operation.<\/p>\n